Aminopurvalanol A

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Aminopurvalanol A  纯度: 98.00%

Aminopurvalanol A 是一种有效的、选择性的、可渗透细胞的 Cyclins/Cdk 复合物抑制剂。Aminopurvalanol A 优先靶向G2/M 期转变进而抑制癌细胞分化。Aminopurvalanol A 通过抑制生理获能依赖性肌动蛋白聚合而抑制精子受精能力。

Aminopurvalanol A

Aminopurvalanol A Chemical Structure

CAS No. : 220792-57-4

规格 价格 是否有货 数量
5 mg ￥1200 In-stock
10 mg ￥2000 In-stock
25 mg ￥3900 In-stock
50 mg ￥6000 In-stock
100 mg ￥9000 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

Aminopurvalanol A 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus
  • Apoptosis Compound Library
  • Cell Cycle/DNA Damage Compound Library
  • Kinase Inhibitor Library
  • Anti-Cancer Compound Library
  • Anti-Aging Compound Library
  • Anti-Breast Cancer Compound Library
  • Anti-Blood Cancer Compound Library

生物活性

Aminopurvalanol A is a potent, selective, and cell permeable inhibitor of Cyclins/Cdk complexes. Aminopurvalanol A preferentially targets the G2/M-phase transition inhibiting cancer cell differentiation. Aminopurvalanol A causes the inhibition of sperm fertilizing ability via the inhibition of physiological capacitation-dependent actin polymerization[1][2].

IC50 & Target

Cyclins/Cdk[1]
体外研究
(In Vitro)

Aminopurvalanol A (5 and 40 μM; 8 hours) inhibits cell growth primarily by arresting the cells in the G2 phase of the cell cycle and, at higher concentration, triggering apoptosis[2].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cycle Analysis[2]

Cell Line: Human U937 leukemic cells
Concentration: 5 and 40 μM
Incubation Time: 8 hours
Result: Increased the number of cells with a 4N DNA content as early as 8 h after the beginning of treatment at 5 μM. 40 μM led to cellular fragmentation and cells with an irregular DNA distribution, characteristic of apoptotic cell populations.

Apoptosis Analysis[2]

Cell Line: Human U937 leukemic cells
Concentration: 5 and 40 μM
Incubation Time: 8 hours
Result: 40 μM Aminopurvalanol A led to apoptosis rather than after the beginning of treatment at 5 μM.

分子量

403.91

Formula

C19H26ClN7O
CAS 号

220792-57-4
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 100 mg/mL (247.58 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.4758 mL 12.3790 mL 24.7580 mL
5 mM 0.4952 mL 2.4758 mL 4.9516 mL
10 mM 0.2476 mL 1.2379 mL 2.4758 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (6.19 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (6.19 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂： 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (6.19 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (6.19 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 Shanghai Jinpan Biotech Co Ltd 网站选购。
参考文献

  • [1]. Bernabò N, et al. Aminopurvalanol A, a Potent, Selective, and Cell Permeable Inhibitor of Cyclins/Cdk Complexes, Causes the Reduction of in Vitro Fertilizing Ability of Boar Spermatozoa, by Negatively Affecting the Capacitation-Dependent Actin Polymerization. Front Physiol. 2017;8:1097.

    [2]. Rosania GR, et al. A cyclin-dependent kinase inhibitor inducing cancer cell differentiation: biochemical identification using Xenopus egg extracts. Proc Natl Acad Sci U S A. 1999;96(9):4797-4802.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务